GlassScriptPhysician profile
Angela Simmerman
NPI 1669843975
$1,730.17
in general payments reported to CMS, 2019-2025
21 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $503 · 2023: $380 · 2024: $263 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $209.75 | 2021-2022 | |
| Novo Nordisk INC | $186.95 | 2021-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $157.29 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Lucid Diagnostics INC. | $124.90 | 2024 | |
| Glaxosmithkline, LLC. | $124.65 | 2021-2025 | Bexsero |
| Exact Sciences Corporation | $117.21 | 2025 | Cologuard Collection Kit |
| Neurelis, INC. | $103.94 | 2023 | Valtoco |
| Amgen INC. | $92.42 | 2021-2022 | |
| Inspire Medical Systems, INC. | $73.21 | 2023 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $65.74 | 2022 | |
| Alnylam Pharmaceuticals INC. | $62.10 | 2023 | Givlaari |
| Sk Life Science, INC. | $60.21 | 2022 | |
| Edwards Lifesciences Corporation | $59.74 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $52.30 | 2025 | Auvelity |
| Corcept Therapeutics | $49.43 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $47.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $37.10 | 2024 | Breztri |
| Supernus Pharmaceuticals, INC. | $30.14 | 2022 | |
| Celgene Corporation | $23.52 | 2021 | |
| Chiesi USA, INC. | $13.84 | 2025 | Filsuvez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Simmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.